Table 4.

Multivariable Regression Model Evaluating Progression-Free Survival After CLAD Onset

Variable	HR (95% CI)	p-value
Age Category
Less than 30	1	Referent
30–39	0.78 (0.18 – 3.38)	0.744
40–49	0.26 (0.06 – 1.13)	0.073
50–59	0.53 (0.15 – 1.81)	0.308
60 and older	0.36 (0.08 – 1.61)	0.180
Female sex	0.49 (0.25 – 0.96)	0.038
Pre-Transplant Diagnosis
COPD	1	Referent
ILD	0.64 (0.29 – 1.40)	0.265
Cystic Fibrosis	0.93 (0.24 – 3.56)	0.917
Other	0.52 (0.17 – 1.63)	0.260
Bilateral Lung Transplant	1.06 (0.48 – 2.37)	0.882
Mesenchymal CFU count ≥10	3.39 (1.55 – 7.39)	0.002
CLAD Phenotype
BOS	1	Referent
RAS	1.16 (0.53 – 2.54)	0.707
Mixed CLAD	0.72 (0.16 – 3.38)	0.682
U-CLAD	1.82 (0.54 – 6.14)	0.333
CLAD Onset <2 years post-transplant	0.79 (0.43 – 1.46)	0.452
CLAD Stage ≥2 at time of BAL	3.54 (1.40 – 8.92)	0.007
DSA Present1	1.03 (0.51 – 2.04)	0.942
BAL Neutrophils >15%2	1.10 (0.56 – 2.14)	0.783

Definition of abbreviations: CLAD = chronic lung allograft dysfunction, COPD = chronic obstructive pulmonary disease, ILD = interstitial lung disease, CFU = colony forming unit, BOS = bronchiolitis obliterans syndrome, RAS = restrictive allograft syndrome, U-CLAD = undefined CLAD phenotype, BAL = bronchoalveolar lavage, DSA = donor specific antibodies

¹DSA presence was defined as mean fluorescence intensity of ≥1000 on single bead antigen testing prior to bronchoscopy

²Identified on bronchoscopy from which the mesenchymal CFU count was measured